Lantern Pharma Enters $4.4 Million Registered Direct Offering, Plans to Spin Off AI Platform

Lantern Pharma (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company, announced a definitive agreement for a registered direct offering expected to generate approximately $4.4 million in gross proceeds. The offering involves the sale of 2,135,923 shares of common stock (or pre-funded warrants in lieu thereof) at $2.06 per share, along with a concurrent private placement of unregistered warrants. The company also revealed plans to create an independent business entity composed of its AI platform, withZeta.ai, and related technologies and personnel.

The capital raised will likely support Lantern's ongoing clinical programs and the spin-off of its AI platform. The company's pipeline includes LP-184, an acylfulvene compound targeting solid tumors; LP-284, a TC-NER targeting compound for hematologic and solid tumors; and LP-300, a cisplatin/ethacraplatin analog being evaluated in the HARMONIC Phase 2 trial for never-smoker patients with relapsed advanced lung adenocarcinoma. LP-184 is also under development for pediatric CNS cancers through Starlight Therapeutics, Lantern's wholly owned CNS-focused subsidiary.

The decision to spin off withZeta.ai into an independent entity marks a significant strategic move. withZeta.ai, described as a multi-agentic AI co-scientist platform, is now commercially available as a subscription-based research platform for the global biomedical and drug development community, representing a new revenue stream for the company. By creating a separate business, Lantern may unlock shareholder value and allow the AI platform to operate with its own strategic focus, potentially attracting partnerships or investments tailored to its technology.

This development is important as it underscores the growing trend of AI-driven drug discovery companies seeking to commercialize their platforms beyond internal pipelines. Lantern's move could provide a template for other biotech firms with proprietary AI tools. The offering details were disclosed in a press release available at https://ibn.fm/6Dy4I. For more information about Lantern Pharma, visit their newsroom at https://ibn.fm/LTRN.

Lantern Pharma operates an AI Center of Excellence in Bengaluru, India, and is headquartered in Dallas, Texas. The company's RADR platform leverages artificial intelligence and machine learning to transform cancer therapy development. As Lantern executes this strategic pivot, investors and industry observers will watch how the spin-off of withZeta.ai evolves and whether it generates sustained revenue growth.